Compare GROV & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | SCYX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 44.4M |
| IPO Year | 2021 | 2014 |
| Metric | GROV | SCYX |
|---|---|---|
| Price | $1.01 | $4.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $36.33 |
| AVG Volume (30 Days) | 78.4K | ★ 282.6K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.26 | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,716,000.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.14 | $977.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $0.66 |
| 52 Week High | $1.57 | $6.09 |
| Indicator | GROV | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 37.46 |
| Support Level | $0.99 | $3.52 |
| Resistance Level | $1.12 | $4.30 |
| Average True Range (ATR) | 0.05 | 0.42 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 22.73 | 3.34 |
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.